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Desquamative Gingivitis: Early Presenting Symptom of Mucocutaneous Disease
Abstract
Desquamation of the gingiva is a sign that may be encountered in clinical practice. Various diseases can
affect the gingival tissues. Mild desquamation that is localized may be associated with mechanical
irritation or induced by trauma. Moderate to severe generalized desquamation associated with ulceration
and erythema may be indicative of a more serious systemic condition. Although often overlooked,
mucocutaneous diseases frequently present with gingival desquamation as an early presenting symptom.
The most common mucocutaneous diseases that affect the oral cavity are lichen planus, pemphigus, and
mucous membrane pemphigoid. This article reviews the etiology, signs and symptoms, and therapies for
these disorders. Increased knowledge of mucocutaneous diseases can help the clinician recognize these
disorders and enable the patient to receive appropriate therapy.
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Desquamative gingivitis: Early presenting symptom of
mucocutaneous disease
Eric T. Stoopler, DMD'fThomas P. Sollecito, DMD 2/Scott S. DeRossi, DMD'
Desquamation of the gingiva is a sign that may be encountered in clinical practice. Various diseases can
affect the gingival tissues. Mild desquamation that is localized may be associated with mechanical irritation
or induced by trauma. Moderate to severe generalized desquamation associated with ulceration and erythema may be indicative of a more serious systemic condition. Although chen overlooked, mucocutaneous
diseases frequently present with gingival desquamation as an early presenting symptom. The most common mucocutaneous diseases that affect the oral cavity are lichen planus, pemphigus, and mucous membrane pemphigoid. This article reviews the etiology, signs and symptoms, and therapies for these disorders. Increased knowledge of mucocutaneous diseases can help the clinician recognize these disorders
and enable the patient to receive appropriate therapy. (Quintessence lnt 2003;34:582-586)
Key words: desquamative gingivitis, erosive lichen planus, mucous membrane pemphigoid, pemphigus
vulgaris, reticular lichen planus

ingival tissue can be differentiated based on its
anatomic position. The free gingiva comprises the
G
gingival tissue at the vestibular and lingual/palatal aspects of the teeth and in health, is coral pink and has
a dull surface and firm consistency.' The attached gingiva extends apically from the free gingiva to the
mucogingival junction, where it becomes contiguous
with the darker red alveolar mucosa. The alveolar mucosa is loosely bound to the underlying bone and is
relatively mobile. The attached gingiva is firm ly adherent to the underlying alveolar bone and in health, is
coral pink and often shows a fine, surface stippling,
giving it the appearance of an orange peel. '
Desquamation or peeling of the epithelial tissue
usually occurs mainly on the free and attached gingiva. Mild cases that are localized and display minimal
loss of tissue with mild erythema and no ulceration
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may be attributed to mechanical abrasion or irritation.
Aggressive toothbrushing or parafunctional habits may
cause these localized forms of gingival desquamation.
Various oral hygiene products may also cause a mild
superficial peeling of the gingiva. Toothpaste hypersensitivity, especially to tartar-control products, has
been reported as an etiology of desquamative gingivitis.2 The patient should be educated on proper toothbrushing techniques and encouraged to discont inue
parafunctional habits if these are the suspected etiologies. More severe desquamation may be generalized
and accompanied by intense erythema and ulcerations
on the free and attached gingiva, as well as the alveolar mucosa. When local factors cannot be attributed to
the etiology of the desquamation, systemic conditions
must be considered. Three common mucocutaneous
diseases that can present with initial symptoms of
desquamative gingivitis (peeling of the gingival tissue
usually accompanied by erythema, ulceration, and
pain) are lichen planus, pemphigus, and mucous membrane pemphigoid. These conditions are immune mediated and are managed via topical and/or systemic
medications. Knowledge of the etiology, signs and
symptoms, and therapies for these diseases will enable
the clinician to more effectively recognize and diagnose these conditions.
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LICHEN PLANUS

Lichen planus (LP) is a relatively common dermatologic disorder that occurs on the skin and oral mucous
membranes. There are several forms of this disease, including reticular, papular, atrophic, bullous, and erosive patterns. This discussion will focus on the reticular and erosive forms of LP.
The reticular form of LP is the most common and
most readily recogn ized form of the disease. It consists
of slightly elevated. fine, whitish lines (Wickham 's
striae) that produce a lacelike lesion.' Reticular LP is
most commonly seen bilat erally on the cheeks and is
usually asymptomatic requiring no treatment.
Erosive LP presents as chronic multiple oral mucosal ulcers. A significant number of cases of erosive
LP presents with an initial sign of erythema and/ or
desquamative gingivitis' Figure 1 demonstrates generalized desquamative gingivitis in a patient diagnosed
with erosive LP. In some cases, the lesions start as
vesicles or bullae (bullous LP), and in others, the disease is characterized solely by erythema or ulcers (erosive LP). The etiology of LP is idiopathic, which distinguishes itself from lichenoid react ions. Li che noid
reactions have a similar clinical presentation to LP but
are differentiated on the basis of the association of the
reactions \vith administration of a drug, systemic disease, or contact allergy, and they may slowly resolve
when the allergen is discontinued or the disease is
t reated. Drugs that have been reported to induce
lichenoid reactions are penicillamine, ACE inhibitors,
and nonsteroidal anti-inflammatory drugs (NSA!Ds),
although, less commonly, numerous other drugs have
been implicated.' Contact allergens such as cinnamon
and peppermint, as well as mercury and gold in select
d e ntal ma t e rials h ave b een reported t o cause a
lichenoid reaction due to contact allergy.' Hepatitis C
is a systemic condition that has been implicated with
induction of LP-Iike lesions•
The diagnos is of LP and lichenoid reactions is
made by biopsy. Three characteristic features of LP are
seen histologically: a dense subepithelial band of lymphocytes; liquefactive degeneration of the basal cell
layer; and areas of hyperorthokeratosis and hyperparakeratosis with a saw tooth appearance to the rete
pegs.1• Lichenoid reactions cannot always be distinguished from LP but may show deep, as well as superficial lymphocytic infiltrat es, rather than the classic
bandlike infiltrate of LP, as well as eosinophils, neutrophils, and plasma cells. Direct immunofluorescence
can be performed mainly to rule out other mucocutaneous diseases, such as pem phigus or mucous membrane pemphigoid. Subepithelial deposits of fibrinogen
are the most consistent feature of LP when analyzed
via immunofluorescence.
Quintessence International

Fig 1

Generalized desquamation and erythema in the maxillary

and mandibular ging1vae of a pat1ent d1agnosed w ith erosive
lichen planus

Treatment of LP/ lichenoid reactions can be wide
ranging. If the patient has been using navoring agents,
they should be advised to discontinue the use of such
products. If the patient has started a new medication
that correlates to the onset of LP, they should discuss
changing classes of medication with their physician.
The erosive type of LP should be managed more aggressively with the use of high potency (fluocinonide)
and ultra high potency (clobetasol) topical steroid
gels. These agents may be placed in an occlusive dental splint that covers the affected area of the gingiva to
increase healing time and decrease pain. Topical
steroid rinses and topical steroids applied to gauze
pads are other methods of administering medication.
Intralesional steroid injections may be necessary to
treat lesions that are recalcitrant to conventional therapy; however, this may be difficult for gingival lesions.
A short course of systemic steroids may be considered
for extremely indolent lesions• Recently, several reports have been published regarding the use of topical
tacrolimus in treating oral lichen planus. Tacrolimus is
an immunosuppressive agent used in the prevention of
solid organ transplant reject ion, and several reports
have been published demonstrating the effectiveness
of the topical formulation in managing oral LP, especially lesions recalcitrant to conventional therapyiD- 13
There is evidence that suggests that patients with erosive LP are of a higher risk for developing squamous
cell carcinoma. Therefore, it is important to evaluate
these patients on a standard recall basis. This recall
should be based on the patient's response to treatment. Areas unresponsive to treatment should be rebiopsied to rule out dysplasia. Often, the recall will be
more frequent than that usually performed for periodontal disease, usually every 1 to 3 months.

583

-

- - Stoopler et at

Fig 2 Generalized 1ntense erythema and areas of desquamation
m the max1llary and mandibular gingivae of a pat1ent diagnosed
w1th pemphigus vulgaris

An important aspect of LP that must be a ppreciated
by the clinician is the chronic nature of this disease.
Lichen planus, when properly managed, can undergo
periods of quiescence where the patient does not experience any symptoms. When the condition becomes
exacerbated, it can cause desquamation of the gingiva,
which may lead to severe and painful gingivitis. This
may cause the patient to neglect daily oral hygiene due
to the painful nature of these symptoms and may, in
turn, lead to an increase in gingival infl ammation and
periodontal disease. More frequen t professional prophylaxis may be indicated. Due to the chronic nature
of LP, periodontal therapy becomes more integral in
the maintenance of oral health in these patients, as
poor periodontal health makes the management of
erosive LP extremely difficult.

PEMPHIGUS

Pemphigus is an autoimmune disease characterized by
blisters, peeling, and erosions of the skin and mucous
membranes. The highest incidence of the disease occurs
in the fifth and sixth decades of life." This discussion
will be limited to the most common fonn of the disease,
pemphigus vulgaris (PV), which accounts for over 80%
of cases. The other fonns of pemphigus are pemphigus
vegetans, pemphigus foliaceus, pemphigus erythematosus, paraneoplastic pemphigus (a condition where patients with neoplasms, such as lymphoma, present wtth
pemphigus), and drug-related pemphigus15 .
.
Lesions associated with PV are mtraeptthehal, and
blister formation is initiated by the binding of IgG aut oantibodies to desmoglein 3, a transmembrane glycoprotein adhesion molecule present on desmosomes.
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O nce desmoglein 3 is bound by the autoantibody,
there is loss of cell-to-cell adhesion and blister formation begins. As blister formation p~ogresses, it results
in a suprabasilar bulla, which can involve loss of large
areas of skin and mucosal>
Initial signs of PV may include generalized desquamative gingivitis, as seen in Fig 2. The classical oral lesion of pemphigus is a thin-walled bulla with associated erythema. The lesions are commonly seen on the
gingival and buccal mucosa, and the edges of the lesion can continue to extend peripherally until they involve large areas of the oral mucosa. It is common for
the oral lesions to present up to 4 months before the
skin lesions appear. If treatment is instituted during
this time, the disease will be easier to control, and the
chance for early remission is enhanced 15
Biopsy is the standard for diagnosing PV. Ideally,
the biopsy specimen should be taken from an intact
vesicle less than 24 hours old. Since these types of lesions are rarely present in t he mouth , t he biopsy
should be taken from the advancing edge of the lesion
where the characteristic suprabasilar splitting of the
epithelium may be observed. A second biopsy specimen should be taken from clinically normal-appearing
int act perilesional mucosa and sent fo r direct immunofluorescene studies (DIP). Direct immunofluorescene is performed by placing fluorescene-labeled
antihuman immunoglobulins over the patient's tissue
specimen in order to detect antibodies bound to the
surface of keratinocytes. If the patient is positive for
PV, the immunofluorescence pattern will reveal a lacelike pattern around the epithelial cells of the tissue
specimen.
The mainstay of treatment is high doses of systemic
corticosteroids. P rednisone is initially used to bring
the disease under control and once this is achieved,
the dose of prednisone is decreased to the lowest possible maintenance level. A critical aspect of patient
management is early diagnosis; this allows the clinician to use lower doses of medication for shorter periods of time to control the disease. Azathioprine and
cyclophosphamide are immunosuppressive drugs used
as adjuvant therapies in conjunction with prednisone
to reduce side effects of the steroid 16 by allowing the
clinician to administer lower doses of systemic steroid.
Studies have shown that adjuvant therapy decreases
mortality when used with systemic corticosteroids. ~ 18
Mycophenolate mofetil, a newer immunosuppressive
drug, has been effective in managing patients resistant
to othe r adjuvants 1 9 Current studies have demonstrated the effectiveness of mycophenolate in combination with prednisone to successfully manage PV
while managing adverse side effects of medication.2o
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MUCOUS MEMBRANE PEMPHIGOID

Mucous membrane pemphigoid (MMP), also commonly referred to as cicatricial pemphigoid, is a
chronic, autoimmune disease that results in mucosal
ulceration and subsequent scarring. It primarily affects
the mucous membranes of patients over the age of 50
and is considered a subepithelial disease' ' Autoantibodies, usually of the lgG class, cause subepithelial
blistering by cleaving fibrils in the basement membrane zone, as well as activating complement and recruiting neutrophils. 21 Subsets of MMP have been
identified using sophisticated immunology testing and
salt-split skin. These subsets are based on the location
and molecular weight of the antigens involved in
M MP, and the majority of cases have antigens on the
epidermal side of salt-split skin.22 Today, MMP is considered a family of closely related autoimmune disorders in which the various autoantigens are found in
the BMZ and are involved in the attachment of basal
epithelial cells to the underlying connective tissue.
Oral manifestations of M M P include desquamative
gingivitis and erosion or ulcerations of buccal and
labial mucosa, palate, and tongue. Figure 3 demonstrates intense erythema and an area of hemorrhage in
the gingiva of a patient with MMP. Extraoral manifestations include ulceration and scarring of the conjunctiva, corneal damage, and mucosal lesions of the genitals, esophagus, larynx, and trachea."' Skin involvement
is seen in a low percentage of patients with MMP''
Any patient suspected of having MMP must have
two biopsy specimens taken for both routine histology
and direct immunofluorescence study. Routine
histopathology will demonstrate sub-basilar cleavage
and immunofluorescence will show positive fluorescence for immunoglobulin and complement in the
basement membrane zone in 50% to 80% of patients."
Clinical correlation with routine and immunofluorescence studies shou ld be interpreted together to arrive
at a diagnosis of MMP.
Management of MMP depends on the severity of
symptoms. Patients with mild oral disease may be
managed by topi cal and intralesional steroids.
Desquamative gingivitis is often managed with topical
steroids in a soft occlusive splint that covers the gingiva. An adverse sequela of chronic topical steroid use
is candida! infection, and the clinician must closely
monitor the patient for development of infection.
If topical therapies prove ineffective, systemic medications may be used for treatment. Like PV, systemic
steroids are often effective. Dapsone is a synthetic sulfone with anti-inflammatory properties that is found
to be most effective in diseases associated with significant neutrophil infiltration. It has been in clinical use
for many years to treat leprosy and malaria. Studies
Quintessence International

Fig 3 Area of hemorrhage and 1ntense erythema m the maxtllary
ging1va of a pat1ent d1agnosed w1th mucous membrane pem phiQOid.

have demonstrated its effectiveness in treating mucous
membrane pemphigoid.2124 The major adverse effect of
dapsone is hemolysis, and pr ior to initiating therapy,
patients should be screened for glucose-6-phosphate
dehydrogenase (G6PD) deficiency. This is a key enzyme that prevents oxidation of hemoglobin to methemoglobin, and individuals who are G6PD deficient
may develop extensive hemolysis. 25 Minocycline, a
member of the tetracycline fami ly of antibiotics, also
has been shown to be effective in treating MMP.2 •
Reported adverse effects include nausea, vomiting,
dizziness, photosensitivity, and hyperpigmentation."
Combination therapies consisting of nicotinamide and
tetracycline also have been reponed as effective therapy for MMP. 27 It is very important for the clinician to
thoroughly examine all skin surfaces and the patient's
eyes to determine the extent of the MM P. If extraoral
manifestations are observed, it is imperative that the
patient be referred to the appropriate specialist for further evaluation. It is important to remember that approximately 10% of patients with MMP will develop
eye lesions which often result in scarring and can lead
to blindness.

CONCLUSION

Gingival desquamation can be indicative of local
trauma/ irritation or systemic disease. Lichen planus,
pemphigus, and mucous membrane pemphigoid are
three mucocutaneous diseases that can present with
gingival desquamation as their initial symptom. With a
comprehensive history and physical exam, as well as
the use of gingival biopsy, diagnosis of these disorders
will not be delayed.
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